Spiroaminodihydrothiazine derivatives
    5.
    发明授权
    Spiroaminodihydrothiazine derivatives 失效
    螺二氨基二氢噻嗪衍生物

    公开(公告)号:US08501733B2

    公开(公告)日:2013-08-06

    申请号:US13055830

    申请日:2009-07-24

    IPC分类号: C07D513/10 A61K31/547

    CPC分类号: C07D513/10

    摘要: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

    摘要翻译: 由通式(I)表示的化合物或其药学上可接受的盐具有Abeta产生抑制作用或BACE1抑制作用,可用作由Abeta引起的神经变性疾病的预防或治疗剂,并以阿尔茨海默病 型痴呆症。

    Fused aminodihydrothiazine derivative
    10.
    发明授权
    Fused aminodihydrothiazine derivative 有权
    融合氨基二氢噻嗪衍生物

    公开(公告)号:US08198269B2

    公开(公告)日:2012-06-12

    申请号:US12568151

    申请日:2009-09-28

    CPC分类号: C07D513/04

    摘要: A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

    摘要翻译: 由通式表示的化合物:其中环A是C 6-14芳基等,L是-NRLCO-等(其中RL是氢原子等),环B是C 6-14芳基 基团等,X是C 1-3亚烷基等,Y是C 1-3亚烷基等,Z是氧原子等,R 1和R 2各自独立地是氢原子等 ,R 3,R 4,R 5和R 6独立地为氢原子,卤素原子等或其药学上可接受的盐或其溶剂合物,具有A&bgr; 产生抑制作用或BACE1抑制作用,可用作由A&Bgr引起的神经变性疾病的治疗剂; 并以阿尔茨海默氏型痴呆为代表。